Form 4 for MGX Metagenomi Therapeutics, Inc.
Accepted 2026-06-10 11:19:56 ET · period of report 2026-06-05 · accession 0001193125-26-265326 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-10 11:19 | 2026-06-05 | MGX | Wein Matthew | See Remarks | S - Sale | $1.30 | -558 | 126.5K | -0.4% | -$724.84 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-05 | S | D | 558 | $1.30 | 126,491 | D | — | — | (F1) These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person on each of April 1, 2024 and April 1, 2025, and does not represent a volitional trade by the Reporting Person. (F2) Includes 1,500 shares acquired under the Company's employee stock purchase plan ("ESPP") on May 29, 2026. |